Verona Pharma Stock Price, News & Analysis (LON:VRP)

GBX 118.51 -1.99 (-1.65 %)
(As of 01/24/2018 02:57 AM ET)
Previous CloseGBX 118.51
Today's RangeN/A
52-Week RangeGBX 100 - GBX 189
VolumeN/A
Average Volume12,462 shs
Market Capitalization£112.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Verona Pharma (LON:VRP)

Verona Pharma logoVerona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.

Receive VRP News and Ratings via Email

Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:VRP
CUSIPN/A
Phone+44-20-32834200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-40.98%
Return on Assets-37.09%

Miscellaneous

EmployeesN/A
Outstanding Shares105,020,000

Verona Pharma (LON:VRP) Frequently Asked Questions

What is Verona Pharma's stock symbol?

Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

Where is Verona Pharma's stock going? Where will Verona Pharma's stock price be in 2018?

5 Wall Street analysts have issued 12 month target prices for Verona Pharma's shares. Their forecasts range from GBX 22 to GBX 327. On average, they anticipate Verona Pharma's share price to reach GBX 130 in the next twelve months. View Analyst Ratings for Verona Pharma.

Who are some of Verona Pharma's key competitors?

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the folowing people:

  • Sven Jan-Anders Karlsson, Chief Executive Officer, Executive Director (Age 60)
  • Kenneth B. Newman M.D., Chief Medical Officer
  • Ben Harber, Company Secretary
  • David Raymond Ebsworth Ph.D., Non-Executive Chairman of the Board (Age 61)
  • Kenneth D. Cunningham M.D., Non-Executive Director (Age 62)
  • Vikas Sinha CPA, Non-Executive Director (Age 53)
  • Anders Ullman M.D., Ph.D., Non-Executive Director (Age 59)

How do I buy Verona Pharma stock?

Shares of Verona Pharma and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Verona Pharma's stock price today?

One share of Verona Pharma stock can currently be purchased for approximately GBX 118.51.

How big of a company is Verona Pharma?

Verona Pharma has a market capitalization of £112.78 million.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.


MarketBeat Community Rating for Verona Pharma (VRP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verona Pharma (LON:VRP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 130GBX 130GBX 80.75GBX 80.75

Verona Pharma (LON:VRP) Consensus Price Target History

Price Target History for Verona Pharma (LON:VRP)
Show:

Dividends

Dividend History for Verona Pharma (LON:VRP)


No dividend announcements for this company have been tracked by MarketBeat.com

Headlines

Verona Pharma (LON VRP) News Headlines

Source:
DateHeadline
Verona Pharma Plc (VRP) Receives Consensus Rating of "Buy" from AnalystsVerona Pharma Plc (VRP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 4 at 4:02 AM
Verona Pharma plc : Block listing Interim ReviewVerona Pharma plc : Block listing Interim Review
finance.yahoo.com - November 30 at 4:29 PM
Insider Buying: Verona Pharma Plc (VRP) Insider Acquires 10,000 Shares of StockInsider Buying: Verona Pharma Plc (VRP) Insider Acquires 10,000 Shares of Stock
www.americanbankingnews.com - November 30 at 10:30 AM
Verona Pharma Plc (VRP) Receives Buy Rating from N+1 SingerVerona Pharma Plc (VRP) Receives Buy Rating from N+1 Singer
www.americanbankingnews.com - November 27 at 9:02 PM
Verona Pharma Plc (VRP) Earns Buy Rating from Verona Pharma Plc (VRP) Earns Buy Rating from
www.americanbankingnews.com - November 19 at 1:40 PM
Verona Pharma Plc (VRP) Given Average Rating of "Buy" by BrokeragesVerona Pharma Plc (VRP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 15 at 10:06 AM
Top-line data from the study now expected in mid-2018Top-line data from the study now expected in mid-2018
globenewswire.com - November 7 at 1:10 PM
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - November 7 at 1:10 PM
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentVerona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
finance.yahoo.com - November 7 at 1:10 PM
Verona Pharma to Present at Two Upcoming Investor ConferencesVerona Pharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - October 31 at 11:57 AM
Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - October 31 at 11:57 AM
Aida Announces First Appointments to Advisory Board with Experts in the Cannabis, Blockchain and Technology Sectors - GlobeNewswire (press release)Aida Announces First Appointments to Advisory Board with Experts in the Cannabis, Blockchain and Technology Sectors - GlobeNewswire (press release)
globenewswire.com - October 18 at 9:13 PM
Can Verona Pharma plc (AIM:VRP) Improve Your Portfolio Returns?Can Verona Pharma plc (AIM:VRP) Improve Your Portfolio Returns?
finance.yahoo.com - September 13 at 11:02 AM
Arix Bioscience plc notes positive trial data from Verona Pharma in COPDArix Bioscience plc notes positive trial data from Verona Pharma in COPD
globenewswire.com - September 7 at 11:01 AM
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
finance.yahoo.com - September 7 at 11:01 AM
Verona Pharma Appoints Stifel as Nominated AdviserVerona Pharma Appoints Stifel as Nominated Adviser
finance.yahoo.com - September 1 at 10:55 AM
Edited Transcript of VRP.L earnings conference call or presentation 8-Aug-17 12:00pm GMTEdited Transcript of VRP.L earnings conference call or presentation 8-Aug-17 12:00pm GMT
finance.yahoo.com - August 11 at 3:55 PM
Verona Pharma Plc (LON:VRP) Scheduled to Post Quarterly Earnings on TuesdayVerona Pharma Plc (LON:VRP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 8:10 PM
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development UpdateVerona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
finance.yahoo.com - August 3 at 8:40 AM
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare ConferenceVerona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 1 at 7:37 AM
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment - NasdaqVerona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment - Nasdaq
www.nasdaq.com - July 28 at 9:47 AM
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD ... - GlobeNewswire (press release)Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD ... - GlobeNewswire (press release)
globenewswire.com - June 29 at 3:16 PM
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patientsDose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients
www.nasdaq.com - June 27 at 4:54 AM
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of ... - NasdaqVerona Pharma Appoints Dr. Desiree Luthman as Vice President of ... - Nasdaq
www.nasdaq.com - June 22 at 2:37 PM
Verona Pharma Announces Closing of Exercise of Underwriters Over-allotment Option - GlobeNewswire (press release)Verona Pharma Announces Closing of Exercise of Underwriters' Over-allotment Option - GlobeNewswire (press release)
globenewswire.com - May 19 at 1:40 PM
Citi Appointed Depositary Bank for Verona Pharma’s ADR ProgrammeCiti Appointed Depositary Bank for Verona Pharma’s ADR Programme
www.businesswire.com - May 3 at 6:52 PM
Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market - GlobeNewswire (press release)Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market - GlobeNewswire (press release)
globenewswire.com - April 28 at 10:35 AM
Verona Pharma Share ChatVerona Pharma Share Chat
www.lse.co.uk - April 1 at 9:48 AM
2 hot growth stocks to buy today on impressive results?2 hot growth stocks to buy today on impressive results?
uk.finance.yahoo.com - February 27 at 8:23 AM
Result of General Meeting and Share Consolidation - London South East (registration) (blog)Result of General Meeting and Share Consolidation - London South East (registration) (blog)
www.lse.co.uk - February 10 at 6:30 AM
Publication of Circular - London South East (registration) (blog)Publication of Circular - London South East (registration) (blog)
www.lse.co.uk - January 18 at 3:45 PM
Half Year 2016 Verona Pharma PLC Earnings Release - Time Not SuppliedHalf Year 2016 Verona Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 13 at 7:20 AM
Half Year 2016 Verona Pharma PLC Earnings Release - Before Market OpenHalf Year 2016 Verona Pharma PLC Earnings Release - Before Market Open
biz.yahoo.com - August 10 at 11:25 AM
VERONA PHARMA PLC - Grant of Share OptionsVERONA PHARMA PLC - Grant of Share Options
www.finanznachrichten.de - August 4 at 11:27 AM
VERONA PHARMA PLC - Notice of GMVERONA PHARMA PLC - Notice of GM
www.finanznachrichten.de - July 2 at 10:43 AM

SEC Filings

Verona Pharma (LON:VRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Verona Pharma (LON VRP) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.